Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi

Pfizer (PFE) announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi.With this nod, the once-weekly Hympavzi is approved for routine prophylaxis (RP) to prevent or reduce the frequency of bleeding episodes in patients aged 12 years and older with hemophilia A or B, without inhibitors to Factor VIII (FVIII) or Factor IX (FIX).The FDA’s approval is based on data from the phase III BAS ...